17:I[66739,["/_next/static/chunks/0.3dg.jzl0xwf.js?dpl=dpl_Hst3gh7MhZkzS6iaknkgT6LpsCH8","/_next/static/chunks/0skdv12y78fnh.js?dpl=dpl_Hst3gh7MhZkzS6iaknkgT6LpsCH8","/_next/static/chunks/10dnvbzcepzg2.js?dpl=dpl_Hst3gh7MhZkzS6iaknkgT6LpsCH8","/_next/static/chunks/0w-9dtq49e_fk.js?dpl=dpl_Hst3gh7MhZkzS6iaknkgT6LpsCH8","/_next/static/chunks/1331nw5i_3lcb.js?dpl=dpl_Hst3gh7MhZkzS6iaknkgT6LpsCH8","/_next/static/chunks/053zyoym-_i67.js?dpl=dpl_Hst3gh7MhZkzS6iaknkgT6LpsCH8"],"default"] 19:I[38632,["/_next/static/chunks/0qqtp3r0h7kah.js?dpl=dpl_Hst3gh7MhZkzS6iaknkgT6LpsCH8","/_next/static/chunks/0iukvycbd42rl.js?dpl=dpl_Hst3gh7MhZkzS6iaknkgT6LpsCH8"],"IconMark"] 18:T43d,

In this episode of Denatured, Jennifer C. Smith-Parker speaks to Maha Katabi, general partner at Sofinnova Investments and Andrew Lam, managing director, head of Biotech Private Equity at Ally Bridge Group, about how M &A dynamics, dealmaking and global partnerships are reshaping portfolio valuations and paths to growth in 2026.

Host

Jennifer Smith-Parker, Director of Insights, BioSpace

Guests

Maha Katabi, General Partner, Sofinnova Investments

Andrew Lam, Managing Director, Head of Biotech Private Equity, Ally Bridge Group (ABG)

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

From Nuclear Winter to Renewal: Biotech Investing for 2026

BioSpace

From Nuclear Winter to Renewal: Biotech Investing for 2026